Cellular Senescence Drives Crohn's Intestinal Fibrosis Through a Double-Edged Mechanism
A comprehensive review reveals how senescent cells both limit and accelerate fibrosis in Crohn's disease, pointing to senolytics as novel antifibrotic therapies.
Riepilogo
This 2026 review in Frontiers in Immunology systematically examines how cellular senescence shapes intestinal fibrosis in Crohn's disease (CD). The authors describe four key triggers of senescence in the CD microenvironment—oxidative stress, telomere dysfunction, endoplasmic reticulum stress, and genotoxic damage—and analyze how each major intestinal cell type (fibroblasts, myofibroblasts, endothelial, epithelial, and immune cells) contributes to fibrotic progression when senescent. Central to this process is the senescence-associated secretory phenotype (SASP), which drives paracrine inflammation, ECM imbalance, and stem cell dysfunction. Crucially, acute senescence can limit fibrosis and aid wound healing, while chronic senescence sustains destructive inflammation. The review concludes by evaluating senolytic and senomorphic therapies as promising antifibrotic strategies for CD patients.
Riepilogo Dettagliato
Crohn's disease (CD) is a chronic gastrointestinal inflammatory disorder affecting a rising global population, with intestinal fibrosis—manifesting as stricturing complications—developing in 30–50% of patients within a decade of diagnosis. Despite advances in biologics and small-molecule therapies, current anti-inflammatory agents show limited efficacy against established fibrosis, and up to 70% of CD patients ultimately require surgical intervention. This landmark review by Liu and Yu (Zhejiang University, 2026) frames cellular senescence as a central, context-dependent driver of this fibrotic burden.
The authors identify four principal triggers of senescence within the CD microenvironment. Oxidative stress, generated by chronic intestinal inflammation, overwhelms antioxidant defenses and induces mitochondrial dysfunction, ROS accumulation, and downstream myofibroblast differentiation. Telomere dysfunction, accelerated by high cellular turnover from persistent inflammation, elicits a sustained DNA damage response that locks cells into senescent arrest. Endoplasmic reticulum (ER) stress—elevated in stenotic versus non-stenotic CD tissue—promotes epithelial and fibroblast senescence via the SIRT1-P300 axis and activates TGF-β/SMAD fibrotic signaling. Finally, genotoxic damage from inflammatory mediators (TGF-β, IL-22) and microbial products reinforces growth arrest and activates further TGF-β signaling, creating a self-amplifying loop.
The review delineates the contributions of distinct senescent cell types. Senescent myofibroblasts and fibroblasts, though proliferatively impaired, hypersecrete profibrotic SASP factors—especially TGF-β1—driving ECM deposition; specialized fibroblast subpopulations marked by CXCL14, MMP/WNT5A, and CTHRC1 act as signaling hubs within fibrotic strictures. Senescent endothelial cells undergo endothelial-to-mesenchymal transition (EndoMT) under TNF-α and TGF-β1, directly fueling tissue fibrosis. Senescent epithelial cells impair barrier integrity and stem cell renewal. Senescent immune cells, including macrophages and lymphocytes, sustain the inflammatory milieu and regulate fibroblast activation through paracrine signaling.
The SASP emerges as the master mediator linking senescence to fibrosis: its cytokines, chemokines, growth factors, and proteases drive paracrine senescence spread, ECM imbalance, immune modulation, and intestinal stem cell dysfunction. A critical conceptual contribution of this review is distinguishing acute/beneficial senescence—which promotes wound healing and limits fibrosis through timely immune clearance—from chronic/detrimental senescence, in which persistent senescent cell accumulation overwhelms clearance mechanisms and drives irreversible fibrotic strictures.
Therapeutically, the authors highlight senolytics (agents that selectively eliminate senescent cells, e.g., navitoclax, dasatinib plus quercetin) and senomorphics (agents that suppress SASP without inducing cell death, e.g., rapamycin, JAK inhibitors) as emerging strategies. Evidence from liver fibrosis models supports targeted reprogramming or elimination of p16Ink4a+ senescent cells as a viable antifibrotic approach. The authors call for further mechanistic studies specific to intestinal fibrosis and translational trials testing senescence-directed interventions in CD.
Risultati Principali
- 30–50% of CD patients develop fibrotic strictures within 10 years; current anti-inflammatory therapies cannot reverse established fibrosis.
- Four senescence triggers converge in CD: oxidative stress, telomere shortening, ER stress, and genotoxic damage from inflammation.
- SASP from senescent fibroblasts, endothelial, and epithelial cells drives ECM deposition, immune dysregulation, and stem cell dysfunction.
- Acute senescence limits fibrosis; chronic senescent cell accumulation drives irreversible intestinal fibrosis—a true double-edged role.
- Senolytics and senomorphics (e.g., navitoclax, rapamycin, JAK inhibitors) represent promising antifibrotic strategies for CD.
Metodologia
This is a comprehensive narrative review synthesizing 252 references from preclinical models, clinical studies, and mechanistic literature. No original experimental data were generated; evidence is drawn from murine fibrosis models, human CD tissue analyses, and cross-organ senescence research.
Limitazioni dello Studio
As a narrative review, it is subject to selection bias and lacks quantitative synthesis (meta-analysis). Most mechanistic evidence is derived from non-intestinal fibrosis models (liver, lung, skin), requiring validation in CD-specific systems. The dual role of senescence complicates therapeutic targeting, as indiscriminate senolytic use could impair beneficial acute senescence and wound healing.
Ti è piaciuto questo riepilogo?
Ricevi ogni settimana le ultime ricerche sulla longevità direttamente nella tua casella email.
Inserisci la tua email per iscriverti: